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Innovation is an integral part of economic development in developed economies.  In 
the post 2008 period, a key policy agenda is that of sustainable development, which 
calls for innovation in all aspects of value-chains.  In this paper, we focus on 
innovation from the biotech – pharma perspective to see whether or not this will lead 
to a sustainable future for the regions where there are clusters of firms in this sector.  
We examine data from a recently completed European Union study of innovation in 
the Healthcare sector from the UK and Switzerland, countries with an historical base 
in pharma, to understand how innovation pathways vary at the regional level in the 
broader life sciences, which incorporate biotech and more.  Innovation in the 
healthcare sector in two regions, Oxfordshire in the UK and Zurich in Switzerland are 
compared.  We contextualize our discussion by drawing on studies that focus on the 
sector in the United States, specifically Boston.  The analytical framework comprises 
three elements: innovation systems and national and regional economic development 
theories are the first two, followed by approaches which consider organizational or 
institutional activity.  This framework is used to help explain and understand the 
complexity of how innovation is organized at the sub-national level.  The overall 
context is that it is increasing becoming a condition for government financing of 
research that it has more immediate application in industry or have the possibility of 
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1. Introduction 
Although innovation is an integral part of economic development in the developed 
economies of Western Europe and the United States, competitive pressures are now 
felt from all around the world, especially the East Asian nations, Brazil, India, and 
Russia.  Both the US and the UK went through industrial restructuring in the 1980s, 
IT revolution in the 1990s, and the biotech craze in the 2000s.  In the post 2008 
economic downturn, the focus is on sustainable development, which calls for further 
innovation in all aspects of value-chains.  In this paper, we focus on innovation 
capacity at the regional level from the life sciences sector, which incorporates the 
biotech/healthcare sector (broadly defined).  The goal is to use a series of innovation 
indicators in specific regions in order to explore cross-national diversity identifying 
where regions are stronger and weaker in their capacities for sustaining innovation 
and competitiveness.  These indicators include institutional factors, political, legal and 
cultural; as well as specific advantages for entrepreneurial activities of public research 
institutes in the case of the biotech/healthcare sector. 
 
Here the indicators are used to examine innovation capacity in Oxfordshire in the UK 
and Zurich in Switzerland - both locations are places which have strong historical 
bases in the biomedical research.  From this evidence, we argue that not all countries 
or regions will converge in terms of future innovation paths and outcomes.  We 
contextualize our discussion by drawing on studies that focus on the sector in the 
United States, specifically Boston, which is one of the three places in the US that are 
at the forefront of innovation in bio-pharma (Breznitz and Anderson 2006).  Boston is 
far in advance of either Oxfordshire or Zurich. 
 
Several theories inform the interpretation of the data.  The analytical framework 
comprises three elements: innovation systems and national and regional economic 
development theories are the first two, followed by approaches which consider 
organizational or institutional activity.  A key theoretical theme is that of historical 
anchor organizations (Feldman 2003).  Anchors in this context include major research 
and industrial organizations, such as universities, hospitals, and big pharmaceutical 
companies.  Their prominence in certain locations relates to the prestige of top 
universities and their ability to attract the best people as well as research income from 
public, private and charitable bodies.  In the case of the big pharma, factors relating to 
the reasons why they were established in certain places and why they stay there 
(national and local factors) are considered.  Conceptually, the paper explores how the 
development of regional specializations in the healthcare sector is associated with 
historical anchors and how and why they might be linked to sustainable innovation 
pathways in the future.  
 
This framework is used to help explain and understand the complexity of innovation 
processes, that is, convergence and divergence in innovation capacity.  The overall 
context is an increasingly made a condition for government finance of research of 
having more immediate application in industry or possibilities of commercialization 
(e.g. translational research). 
 
The data are drawn from a recently completed five country European project, 
HealthTIES (2010-2013)
1
, the objective of which was to identify how regions differ 
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in their strengths and weaknesses in order to inform policy.  Four regions were chosen 
on the basis that that they are four of the top bioscience & technology regions in 
Europe and combine clinical science with engineering science, businesses, regional 
authorities, and well-established Bioscience Parks (the others being Leiden-Delft, 
Netherlands, and Biocat in Spain).  The fifth was a developing region in Hungary.  
The two regions here were chosen to illustrate the value of the methodology in two 
places with some similar attributes, and to show how innovations arise from 
geographic specificities of local investors, major research universities, existing companies 
and highly skilled labor markets.   
 
We show that Zurich performs better on most indicators than Oxfordshire, having 
elements of both early and late stage biotech and pharmaceutical sector activity.  
However, a limitation of all of these kinds of study is that they are not able to 
demonstrate the effects of location with regard to the broader geographical context. 
For example, Oxfordshire is only one part of the Golden Triangle of Oxford, 
Cambridge and London universities which collectively have large scale research 
strengths.  Zurich is a major centre of the country’s biopharma industry and is not far 
away from Basel where the headquarters of three of the world’s largest companies are 
located and might be seen as being in competition for resources and firms.  We 
therefore argue that both cases highlight the complexity of speculating on future local 
growth trajectories in a particular sector in isolation from its broader geography. 
 
2. Explaining the development of innovation capacity 
Three geographic scales, the country, the region (locality) and the organization, are 
considered to understand where spillovers in the form of symbiotic relationships 
between local firms and other organizations (Agarwal et al. 2007) are found and 
utilized to create entrepreneurship and innovation.  In innovation theory, national 
innovation systems provide the context – the regulatory system, funding for the 
science base, and the university sector.  However, some countries have very strong 
regional systems such as Länder in Germany and regions in France that develop their 
own science policies (Perry and May 2007).  Within those two are sectoral systems, 
which describe the sectoral specifics of non-linear paths from research to 
commercialization (value chain) within the local geographic context (micro 
geographies), which are sustained by the macro (country) and meso (region/state) but 
also sustain the macro and the meso through feedback loops for sustainable policy 
development.  An example is the Massachusetts Biotechnology Council, MassBio
2
, 
and its operations to connect organizations operating at various geographic scales.  
Within each location reside the specific organizations with variegated cultures of 
collaboration: firms, universities and industry specific coordination bodies.  Within 
this context, we are interested in what guides institutions to stimulate entrepreneurial 
activity and commercialization based on their cross-national diversity.  In other 
words, what is national, what is regional and what are the organizational 
characteristics that matter in understanding pathways of innovation in the broader 
healthcare sector? 
 
2.1 National systems of innovation 
The national context has one major element often overlooked, that is, wealth creation 
through industrial development in the 20
th
 century.  Then, pharmaceutical companies 
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emerged in Europe and the United States.  In the post World War II period, 
universities and institutes forged ahead with R&D in various science, technology, 
engineering and medical disciplines.  These trends created centers of high technology 
and geographic clusters of high tech industries, which are well documented by Porter 
(1998), Feldman (2000, 2003) and others.  Within these clusters, studies have shown 
that various trajectories have developed indicating that, even if the initial input is 
more or less the same, clusters or regions can take different paths, grow, die, remain 
closed or become open (see for example Asheim et al. 2006).   
 
In the mid 20
th
 century, the role of government emerged as Keynesian views received 
broader acceptance.  This has continued with many ups and downs.  Science and 
technology policy at various scales have created anchor institutions that lead to 
possibilities for innovation at the local level with far reaching impacts for 
collaboration and human development (e.g., National Institutes of Health (NIH) in the 
United States). 
 
National innovation systems’ (Freeman 1995, Lundvall 1988 & 1992, Nelson 1988 
and 1993) analysis of inputs and outputs into an innovation system includes industries 
and firms (the central elements of the system) but also actors and organizations 
including the research base in science and technology as well as 
innovation/technology policy (Carlsson et al. 1999).  The national innovation system 
essentially consists of three sectors: industry, universities, and the government, with 
each sector interacting with the other, while at the same time having an independent 
existence (Goto 2000) - the Triple Helix model describes these relationships in greater 
detail (Etzkowitz and Leydesdorff 1995).  
 Within national contexts, we can trace such institutions from the Fordist era, the 
information technology revolution, the biotech revolution to the current life sciences 
focus with a goal toward sustaining and improving health and human development.  
However, the specific difference between life sciences and other clusters is the 
specific requirements relating to the capital infrastructure, including lab facilities 
(e.g., wet labs), health and safety regulations, people with formal scientific 
qualifications and the realization that many innovations come directly out of 
university labs to patients/hospitals.  Typically, a biological agent is discovered in a 
university lab and is patented.  Then, a licensing agreement with a company is 
reached for commercialization (Breznitz and Anderson 2006). 
 
The research base or universities are central players in national systems of innovation, 
having broadened their scope to be noted for their societal role of creating wealth 
through making the applications of their research accessible for commercialization 
(Etkzowitz 1983, Shane 2004, Clarysse et al. 2011).  Switzerland and the UK are 
renowned for their strengths in the pharmaceutical sector as well as their science base 




The US national innovation system (Atkinson 2014) includes the business 
environment, the regulatory environment and the innovation policy environment.  In 
the business environment, key factors are managerial talent, adoption of ICT across 
the value chain in most industries and venture capital.  Atkinson finds that the US is 
                                                          
3
 http://www.swissbiotech.org/Php5/aa2/UserFiles/File/pdf/swissbiotechreport/SBR_2014.pdf accessed 
November 26 2014) 
the world leader in all three.  While most venture capital placements are concentrated 
in a few states e.g. California and Massachusetts, there is some venture funding in 
almost every state.  There is also a robust business angel system in the US.  However, 
Atkinson finds that, although university is supported through a number of agencies 
such as the Department of Defense and the NIH, university research income has fallen 
behind competitor countries.  This is because of cuts at state and at Federal 
government levels.  This decline in investment has potential consequences for the 
future of university research (Atkinson 2014). 
 
National R&D spending is often attributed to cross-country differences in innovation 
and high technology productivity (Fagerberg et al. 2014).  In Europe, the 2000 Lisbon 
strategy of setting a target of increasing member states’ R&D investment to 3% was 
influenced by the observation that the US share of R&D to GDP is almost double the 
European level.  However, the authors argue that social, institutional and economic 
factors need to be in place to absorb R&D investments.  Moreover, Fagerberg et al. 
(2014) suggest that comparisons between European countries and the US are 
unrealistic and a better comparison would be between individual US states and 
European countries or between European nations.  For example, Massachusetts 
invests nearly 4% of its GDP on R&D, which is the same as Sweden.  It is also the 
case that different sectors have different levels of R&D intensity.  Although R&D 
intensity is a commonly recognized indicator, the relationship between R&D intensity 
and innovation is not clear cut in biotechnology given the lag in translating research 
into commercializable products. 
 
Indicators at national level seem to be important for small European countries.  
However, almost every country has a particular city or a region that has captured the 
value chain activities (from research to production), which is indicative of 
agglomeration economies or historic development of anchor institutions, policy, 
related infrastructures, and labour markets.  Some dispersal is present, but the recent 
phenomenon of intense clustering cannot be ignored in places such as Zurich and 
Oxford.  In each, as we will show later, they are underpinned by healthcare 
infrastructure, research systems and to varying extent the commercial components of 
the sectoral innovation system (big pharma, subsidiaries and biotech firms).  In turn 
these regional characteristics define the localities’ positions within national (and 
international) systems of innovation. 
 
2.2 The regional level 
In recent literature on high technology and biopharma, the focus has been on 
understanding what differentiates the high performing regions from the periphery or 
ordinary regions.  The evolutionary economic geography literature discusses regional 
pathways (see for example Boschma and Frenken 2011).  In this context, these 
pathways in translational research point to outputs that indicate what the innovation 
chain looks like in the broader healthcare sector, that is, the directions it is taking and 
the specialisations in research. They also raise the question of why some are more 
effective than others in translating into commercial products.  Big pharma and its 
subsidiaries, biotech firms, universities of which parts of the innovation system are 
present in each region, are significant in determining pathways - or indicate how 
regions are differentiated in terms of resources, networks, outputs and so on. 
 
Questions concerning national and regional factors that facilitate coordinating 
functions among various actors involved in the innovation process and create 
spillovers, are the basis of many studies in the field of innovation studies (Agrawal et 
al. 2007).  A region’s diffusion (or spillover) capacity works alongside its capability 
to absorb knowledge external and internal to the region (firms and research 
organisations), its level of skills, as well as its institutional quality (number and 
quality of knowledge institutions, R&D and innovation activities and networks) 
(Wintjes and Hollanders 2011).  Developing and sustaining technologies may be 
affected by location, for example the size of the local market, activity of proximate 
actors, regional specialization that allows for economies of scale, and technological 
capabilities (Fagerberg et al. 2014).  Technology spillovers in which universities are 
active participants in various ways as the case in the Boston area biotech sector are 
another type of context (Breznitz and Anderson 2006).  Autant-Bernard et al. (2006) 
found that high levels of scientific activity within a region are necessary to sustain a 
continuous flow of new business creation in the biotech sector 
 
Typically, such clusters have vertical (customers and suppliers) and horizontal 
(producers of complementary products and specialist infrastructure) dimensions.  
Depending upon their sophistication, they might include other public and private 
institutions as well as trade associations and regulatory agencies that provide 
specialized training, information and technical support (Tracey et al. 2004).  How 
regional trends, trajectories or pathways are developed varies with the local context 
(Lawton Smith and Bagchi-Sen 2010, Casper 2013).  A factor in this variety is the 
role of local stakeholders (e.g., entrepreneurs, intermediaries) who have been argued 
to be key in the creation of networks which build capacity and sustain regional 
economic development (Feldman 2014). 
 
The regional systems of innovation (RIS) concept (Cooke et al. 1992, 1998) captures 
the importance of location-specific inputs, system elements and outcomes in 
geographies of innovation.  However, it neither focuses on technology nor on sectors 
but on the growth trajectories of regions taking into account broader 
industrial/sectoral, institutional and research contexts.  A RIS consists of “interacting 
knowledge generation and exploitation subsystems linked to global, national and 
other regional systems” that may stretch across several sectors in the regional 
economy (Asheim and Coenen 2005, 1174).  Regional government and innovation 
infrastructure are main agents of a RIS - the geographical dimension is the element of 
distinctiveness.  Important elements are the spillovers associated with clustering 
effects.  The indicators – specialized labor markets, clustering of firms in the supply 
chain giving rise to knowledge spillovers, infrastructure – show that the whole is 
greater than the sum of parts (Spencer 2013).  Context conditions include resources of 
the area before building of a cluster or a pathway – local scientific and technological 
resources in academia and industry, industry specificities, specific composition of 
local firms in the sector, their origins and linkages, specifically presence of large 
global firms, infrastructure, existing partnerships and institutions facilitating 
cooperation (Weil et al. 2010). 
 
A main characteristic of the regional geography of the broader healthcare sector is the 
clustering of biotech firms around the research universities with large engineering and 
medical schools.  The RIS approach takes into account a much wider set of 
knowledge transfer mechanisms which account for this clustering.  These include 
contract research, formal R&D co-operations and forms of knowledge transmission 
that are indirect such as knowledge spillovers (through the provision of graduates to 
the local labour market), and informal contacts with firms.  
 
Capabilities of institutions are seen as a bundle of knowledge.  Both firm and 
university level capabilities can include patents, while university equivalents of 
business R&D and financing of innovation (Fagerberg et al. 2014) could be research 
income and expenditure.  On their three indicators of technological capability 
(patents, business R&D and venture capital) Massachusetts topped the rankings 
(2008) with Switzerland 10
th
, with only Sweden above it in the top 10 rankings, the 
others being US states.  This ranking shows that on average technological capability is 
higher on average at state level in the US when compared to whole countries in 
Europe.  Fagerberg et al. also examined social capabilities – social, institutional 
dynamics and political characteristics.  They found that when these are taken into 
consideration in the form of knowledge infrastructure indicators of the science system 
(scientific publishing), university R&D expenditures, government R&D expenditures 
and tertiary education, the US led except in the area of university R&D, whereas 
government R&D was much higher.  Overall, the knowledge infrastructure benefitted 
high-tech regions in the US disproportionately.  However, Fagerberg et al. (2014) 
concluded that most European countries, particularly the top performers, are just as   
 
2.3 The organizational level 
The effects of anchor institutions including firms and universities in local 
development have been found to be stronger when they are located in close proximity 
with enterprising firms and other stakeholders such as firms providing professional 
services and local public policy organizations.  The theory of the Anchor Firm 
originally applied to the development of shopping malls.  Since then it has been 
applied to a both low and high tech sectors shopping malls (Konishi and Sandfort, 
2003), R&D intensive firms (Agrawal & Cockburn, 2003), the aircraft industry (Niosi 
and Zhegu, 2010) and the biotech industry (Feldman, 2003).  Existing firms can serve 
as anchors that attract skilled labor pools, specialized intermediate industries and 
provide knowledge spillovers that benefit new technology intensive firms in the 
region.  This can positively affect firm survival and growth and subsequently the 
viability of the regional clusters (Feldman, 2003).  
 
The presence of large global firms within a local economy under some circumstances 
can act as catalysts for innovation, labor force development and trade (Spencer 2013, 
see also Markusen 1996).  An anchor, in the form of a large, established firm 
therefore may create externalities that benefit agglomerations.  These can create local 
advantages such as pools of skilled labor and demand for specialized products, which 
may benefit smaller start-up firms (Feldman, 2003).  They can produce positive 
agglomeration effects on a region by spinning off new local innovative firms and by 
attracting other innovative firms to the region (Niosi and Zhegu, 2010).  FRIDA 
(2014) also concluded that anchor firms and the networks they create constitute ‘key 
drivers’ of the European Union’s 2020 growth strategy.  The anchor firms have the 
capacity to upgrade local economies and thereby contribute to a more dynamic 
economy in Europe overall.
4   
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 Feldman (2003) considered the locational dynamics of the US biotech industry in 
relation to the anchor firm hypothesis.  For the US biotech industry, the geographic 
location of the industry appears to be anchored by some large institutions, related 
firms and successful early entrants to the industry.  More generally, regional anchors 
may encompass other institutions such as universities, government labs, research 
institutes and other entities (Feldman, 2003).  What is important is the extent to which 
they work with other parts of the value chain to enable their locations to function as 
places of high efficiency in the creation, transfer and application of knowledge 
(Breznitz and Anderson 2006).  
 
More recently, Spencer (2013) set out to test whether proximity delivers superior 
advantages for smaller businesses and entrepreneurial activity in four sectors in 
Canada, including bio-pharma.  This sector in Canada, as in the US, is mainly 
clustered in large urban areas, with educated populations and top-rate research 
institutions, and relies less on material inputs and more on knowledge for 
competitiveness.  He found, however, that there was not enough strong evidence to 
suggest that close proximity to anchor firms made a significant difference to firm 
performance.  This finding is relevant to the regions in this study. 
 
This finding provides further justification for study of how the presence of a 
university as an anchor institution in a locality affects the behavior of its academics 
and the potential for fostering network activities in the broader healthcare sector, 
which includes bio-pharma.  While this implies that such networks occur 
spontaneously, often the process of making networks requires facilitation.  A 
facilitating process can include academic engagement - which represents an important 
way by which academic knowledge is transferred – or translated – into the industrial 
domain (Perkmann et al. 2014).  These authors that show the forms that it takes is 
related to the characteristics of individuals as well as the organizational and 
institutional contexts in which they work.  The motives and outcomes for university 
and industry interactions in the UK are also examined by Ankrah et al. (2013).  They 
found a match of motives and beneficial outcomes for university and industry actors, 
in spite of differing work environments.  Thus government funding for collaboration 
was justified by the benefits to individual organisations (rather than societal benefits). 
 
However, organizational behavior and academic links with industry vary by academic 
experience and by place (Jong 2008, 2012 & Jong and Slavova 2014). Jong (2008) 
finds differences in the behavior of therapeutic biotech firms in Cambridge and 
Munich that have relied on their institutional environments differently to develop their 
capabilities.  Differences include for example in accessing investment finance (public 
funding is present in Munich but not in Cambridge), finding CEOs – Cambridge but 
not Munich firms recruited mostly from the national pharmaceutical industry, and in 
networking - Cambridge firms less likely to be part of academic knowledge networks 
in their local region than those in Munich, and are less likely to publish with 
academics.  Later, Jong and Slavova (2014) found that a firm’s involvement in 
academic communities enhances its innovation performance, and that co-publishing 
and collaboration positively affects firm innovation.  Therefore it can be concluded 
from both Perkmann et al. (2013), and Jong and Slavona (2014) that there are gains to 
both firms and academia in ‘open science’ activities but that organizational and 
institutional characteristics have been found to have an effect on the extent and nature 
of universities as anchor institutions in particular places. 
 
The section below presents the description of the data used to compare the two 
example regions: Oxfordshire and Zurich.  First, the data source is described.  Second, 
each of the two regions are characterized based on a discussion of their national and 
regional system of innovation as well as specific local characteristics.  Third, regional 
comparisons of inputs, innovation system/structure, and outputs are presented for the 
broader life sciences.  Fourth, these two regions are set against one of the leaders in 
bio-pharma innovation – Boston.  A discussion of the regional characteristics of 
Boston is followed by a comparison of the three regions across several areas of 
specialization in life sciences to show possibilities for collaboration or lack thereof. 
 
3. Methodology, Data, and Findings 
3.1 Methodology and Data  
One of the key problems in comparing regions is the availability of comparable data 
as reliable indicators of a particular phenomenon.  In this study, the Innovation 
Indicators illustrating the three regions are based on those developed by the 
Healthcare, Technology, Innovation and Economic Success (HealthTIES) project. 
This was an EU FP7 funded study (2010-2013) which aimed to identify key elements 
in the functioning of healthcare technology innovation systems with a view to 
speeding up these systems.  The project included bioscience regions in four core 
countries centred around the following cities: Leiden, Rotterdam and Delft (Medical 
Delta; Netherlands), Oxford, (UK), Barcelona (Spain) and Zurich (Switzerland) along 
with an emerging region in Eastern Hungary, Debrecen.  
 The Innovation Indicators were specific to the disciplines of biotech, medtech, life 
sciences and medical sciences.  Data relevant to inputs, innovation system and outputs 
were collected on universities, research institutes, intermediate vocational education, 
care providers, public and private funding, industry, technology transfer and science 
parks.  Additionally, publications and citations (combined in the h-index; Hirsch, 
2005) were used to describe the disease and technology platform indicators (data for 
Boston were collected for disease and technology platforms out of interest as a 
comparator as Boston was not included in the HealthTIES project).  These data were 
quantitative, discriminatory and primarily in the public domain.  A further intention of 
developing the indicators was their application to similar clusters in other countries so 
that comparisons could be made using a variety of statistical and graphical 
techniques
5
.  The data presented here were primarily collected for 2010: other time 
periods are indicated in the tables.  We include the data for the three stages of the 
innovation cycle (Tables 1-3) and h-indices for diseases and technology platforms 
(Table 4).   
 
3.2 Regional Contexts 
3.2.1 Oxfordshire/UK 
Oxfordshire’s population is approximately 2.7 million.  It is the leading component of 
the South East of England research, educational, health and life science cluster 
(population 8.3 million), that continues to be the fastest growing region in the UK.  
Oxfordshire is one of the UK’s leading clusters.  The others are Cambridgeshire in 
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East Anglia, London and Eastern/central Scotland (Edinburgh, Dundee).  Its path of 
development has been influenced by national policy which reinforces clustering in a 
few regions which have hospitals as well as leading universities and a biotech 
infrastructure.  This effectively means that Oxfordshire (along with London, 
Cambridge and Central Scotland) will continue to be leading biomedical regions 
(Minshall and Wicksteed 2005).  
 
According to the UK BioIndustry Association, the UK’s strength in life sciences lies 
in it having “4 of the top 10 universities in the world, 19 of the top 100 universities, a 
stable of quality service providers, world class charitable supporters of the industry 
and a rich heritage of globally recognized medical research”6.  The pharmaceutical 
industry has a long history in the UK dating back to the 1840s. Major UK 
pharmaceutical companies now include GlaxoSmithKline and AstraZeneca, and 
smaller ones such Kent Pharmaceuticals.  Consolidation in the form of mergers and 
acquisitions has reduced the number of big pharma and biotech companies.  For 
example Celltech was bought out by the Belgian firm UCB in 2004. In 2011, the 
government launched its strategy for UK Life Sciences designed to support 
companies through every stage of the product life cycle.  This is of interest because it 
highlighted weaknesses in the UK healthcare innovation cycle for R&D funding for 
translational activities or the “translational funding gap”7.  A more recent report (HM 
Government 2014)
8
 identified two particular measures to support the industry.  The 
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first is the Accelerated Access Review into Innovative Medicines and Medical 
Technology for which work has begun on mapping the UK landscape and 
international benchmarking.  The second is the creation of “test beds” for the 
assessment and adoption of 21st Century life science innovation in the real time 
patient population as set out in the NHS’s five year forward view.  These sit alongside 
improving the business environment in order to attract life sciences companies to set 
up and expand in the UK. 
 
It has been estimated that £1.2bn has been invested in the Oxford biotech sector in the 
period between 2010 and 2013.  Hence Oxfordshire is a growing focal point of the 
UK national innovation system (Lundvall 1992, Nelson 1992) in biomedical research, 
and as we show below, of a local, national and international sectoral system of 
innovation, comprising firms and a rapidly growing and important sector specific 
network (Romeo and Lawton Smith 2014).  
 
Oxfordshire’s place–specific trajectory in biotech/healthcare lies in the dominance of 
University of Oxford, one of the top five of universities in the world.  During the first 
part of the 2000s, continuous long term government investment supported university 
and biotech research centers making the University of Oxford one of the largest 
biotech environments in Europe with more than 2500 members of staff and 800 
postgraduate students in medical sciences, pharmaceutical studies and biotechnology 
degrees (Lawton Smith, 2014).  This key component of the system (national but 
working sectorally at the local level, Carlsson et al. 1999) has promoted a world 
leading cluster of biotech research and biotech firms (as in the US and Canada, 
Spencer 2013).  
 The research base has undergone institutional change due to the search for greater 
efficiency and effectiveness in translational research. For example, the partnership 
between the University of Oxford and its clinical partners in the form of the NIHR 
Oxford Biomedical Research Centre (BRC) focuses upon 14 research themes, 
incorporating 11 disease themes and 3 cross-cutting themes providing technology and 
innovation platforms and infrastructure with broad application across the clinical 
themes (clinical imaging, molecular genetics including high throughput sequencing 
and bioengineering).  At the regional level, the Thames Valley Comprehensive Local 
Research Network (TVCLRN) brings together 6 universities and 15 NHS 
organizations and provides support for the dissemination of clinical trials and other 
well designed studies in all areas of disease and clinical need.  A major theme is 
translational research involving the rapid early-stage development and assessment of 
new vaccines in clinical trials, including new influenza strains.  
 
During the period 2000-2009, the cluster became a recognized worldwide biotech 
hub, comprising over 200 mostly small local firms.  Although Oxford University, 
since 1997 Isis Innovation, Oxford University’s technology transfer company, has 
incubated several biotech companies in Oxfordshire, other biotech companies started 
in Oxfordshire were independent of the university (Lawton Smith 2005, Lawton 
Smith et al. 2008).  A number of local firms have been acquired by international 
companies such as Novartis (Switzerland) and Siemens (Germany).  In the case of the 
former, the Oxfordshire operations were largely closed down. In the case of the latter, 
in 2003 Siemens acquired the 49% remaining shares in a company making magnets 
for medical technologies (OMT).  This formerly local company, is still to some extent 
an anchor firm (Feldman 2003), being a world centre for design and R&D in magnet 
technology. 
 
The Life Science group accounts for 56% of all companies.  The Medical Technology 
group accounts for the remaining 44%.  Looking at the evolution of these two groups 
over time in terms of company formation, it is also noteworthy that the Life Science 
group, initially the largest one, has become progressively less dominant.  This also 
indicates how the characteristics or attributes of the system are changing (Carlsson et 
al. 1999).  However, the industry mix does not include either the research or 
production activities of big pharma anchor firms – which are represented to a greater 
extent in Cambridgeshire.  For example in 2013, AstraZeneca announced the move of 




In spite of the strong focus on R&D, the region lacks capabilities in 
commercialization as indicated by the much smaller number of biotech companies 
than in Zurich.  This shows that the basic conditions in Oxfordshire are very different 
from Zurich.  While Oxford University dominates and its translational trajectory is 
predicated on its very strong science base, the institutional support system is limited.  
Moreover, the lack of large R&D intensive firms in the life sciences sector is 
particularly distinctive of how the overall biomedical sectoral system of innovation 
(Malerba 2002) functions in this location.  However, at the sectoral level, a bioscience 
network, OBN, a membership organization – has grown as the sector as expanded.  
OBN is the main body which coordinates industry actors (firms, professional service 
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providers and so on)  supporting and bringing together the UK’s emerging life 
sciences companies, corporate partners and investors
10
.  Although there are elements 
of cluster activity relating to the knowledge base, there is therefore evidence of 
incomplete knowledge chains and infrastructure which are more developed in Zurich 
and Massachusetts (below).  What is also missing is an integrated regional innovation 
system that brings together other local actors such as the county’s local authorities 
and the universities in which there is collective leverage to bring about greater levels 
of investment across the board (Asheim and Coenen 2005). 
 
 3.2.2 Zurich/Switzerland 
Switzerland is the most competitive business location in the world according to the 
‘Global Competitiveness Report 2013’.  Switzerland even more than the UK is 
renowned for its strengths in the pharmaceutical sector as well as its science base in 
biomedical science and its developing national biotech chain.   
 
However, the chemical and pharmaceutical sector has a very small Swiss domestic 
market: Europe (35%), America (40 %) and Asia (23 %) account for the majority of 
the sales destinations
11
.  Rather different to other countries, 90 % of the Swiss 
chemical industry's overall product portfolio are specialties and cover some seven 
main areas including Pharmaceuticals and diagnostics (56% of product markets).  
This is a considerable proportion compared to international averages.  Since 1990, the 
pharmaceutical sector has increased its exports by a factor of seven (in terms of 
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value), and it now contributes more than 30% of Switzerland’s total exports12.  Major 
companies with R&D and manufacturing operations include Roche, Novartis, Pfizer 
and Merck Serono.  The chemical and pharmaceutical industry is composed of 
companies of different size.  In addition to the well-known large companies, the 
sector consists of around 1000 smaller and medium-sized enterprises, geographically 
spread over the whole of Switzerland, though with a concentration in the north-
western region. 95% of all companies in Switzerland employ less than 250 persons; 
only around a dozen companies have a workforce of more than 1000. 
 
The main features of the area are its anchor institutions (universities, R&D centers 
and major firms), and more recently a system of coordination - Life Science Zurich 
(LSZ).  Zurich hosts more than 90 internationally well-positioned R&D institutes and 
26 clinics and has about 1.3 million people. ETHZ, University of Zurich has the 
highest university ranking in continental Europe.  Zurich University of Applied 
Sciences, life science division is placed within the top 20 globally.  The University 
Hospital of Zurich (USZ) is the most important of about 25 major hospitals in the 
Canton of Zurich, and the Paul Scherrer Institute (PSI) has a third-generation 
synchrotron light source facility for research in materials science, biology and 
chemistry.  
 
There are some 4800 healthcare companies in the Canton.  In addition, most 
universities have their own internal incubation programs, allowing young companies 
to develop business ideas whilst using the scientific infrastructure in the initial stages 
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and finally to profit from supportive technology transfer circumstances.  Life 
sciences, especially the pharmaceutical industry in Switzerland, play an important role 
in this development.  LSZ is a virtual region with a small physical co-ordination base.  
It was established in 2001 by University of Zurich and the Federal Institute of 
Technology Zurich (ETHZ).  It aims to establish co-operation networks bringing 
together academia, industry and the public sector, and support science education.  
Approximately 80 % of the cluster activities are related to human health.  It is the 
headquarters of the anchor firm Pfizer AG and is the location of the Roche Innovation 
Center Zurich, which has a multinational team of some 140 employees – 95% of whom 
are research scientists13.  
 
3.3 Comparative Inputs, Infrastructure, and Outputs in Oxfordshire and Zurich 
 
Generally the data show a snapshots of each location at 2010, or periods leading up to 
2010.  Without repeated measures, we cannot infer how stable, typical on average, or 
dynamic any of the regions are for any of the indicators, but the results are directly 
comparable, detailed and objective.  Knowledge and research funding patterns (see 
Table 1) show that for professors with an h-index equal to or greater than 30, the 
Oxford (238) and Zurich (231) numbers are comparable.  In contrast, in the total 
number of publications in high impact journals (2001-2010), Oxford significantly 
exceeds Zurich (2264 versus 1190).  This reflects Oxford’s position in the world 





 and UoZ: 44
th
.  However, Harvard and MIT – both Boston 
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addresses - are ranked 1
st
 and 2
nd14).  However, Oxford’s ranking in high impact 
journals is based on a lower level of research funding whereas the total value of 
Zurich exceeds Oxford (1042 over 632 mio Euro).  The pressure on UK academics is 
extremely high due to public sources of funding based on periodic national 
assessments of UK Higher Institutions’ research in which publication in top journals 
is a key component (Research Excellence Framework, 2014)
15
 which is not as clearly 
present in Switzerland.  Therefore, in principle, both have the high levels of scientific 
activity necessary to sustain flows of new business activities (Autant-Bernard et al. 
2006), even though outcomes are different (see below). 
 
Table 1 here 
 
With respect to human capital in the life sciences, Zurich exceeds the total number for 
Oxford in graduate students, particularly for international students.  This may just 
reflect the capacity of support in Zurich.  Moreover, in terms of senior ERC grants, 
Zurich is a long way ahead of Oxford while the amount of grants for junior scientists 
is comparable.  This shows that early career support is competitive in Oxford.  This 
demonstrates a difference in spillover capacity in relation to the quantity (supply) and 
characteristics of the skill base (Agrawal et al. 2007, Spencer 2013, Feldman 2014) in 
the two locations.  
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In terms of healthcare infrastructure, the data show that Oxford has the lead in clinical 
trials, but the areas available for research in universities and research beds in hospitals 
are larger in Zurich, whereas Oxford has a more general facility.  Indictors of 
innovation systems, patents, spinoffs, private projects and TTO are shown in Table 2.  
The overall science park space and personnel support is greater in Oxford, reflecting 
the presence of the Oxford Science Park in Oxford, Oxford University’s own science 
park at Begbroke and two major sites to the south of the county at Milton Park 
(privately owned) and the Harwell Science and Innovation Campus, located on part of 
what was United Kingdom Atomic Energy land.  With respect to technology transfer 
personnel, Oxford leads Zurich.  However, patent and spin off numbers are not 
drastically different with Oxford having a slight lead.  More tellingly Zurich has the 
lead in public-private collaboration indicating that there is a more effective 
knowledge diffusion process through interaction with industry (Agrawal et al. 2007).   
 




Consistent with the input data in Table 1, the picture on output shows that Oxford is 
ahead at the exploration phase while Zurich is ahead in the exploitation phase (see 
Table 3).  Zurich has more biotech companies and products on the market while 
Oxford leads in clinical trials, discovery phase products, investments especially series 
A investments etc.  Oxford fits our understanding (see Cooke 2001) of a 
place/institution with early phase focus while Zurich fits the late phase focus.  Zurich 
has the advantage of having the knowledge to take products to market and it is not far 
behind in discovery phase numbers, patents etc.  Zurich has better opportunities for 
benefitting from more industrial engagement leading to innovation within its system. 
 
Table 3 here 
 
Zurich also benefits from its relatively close proximity to Basel (c50 miles) – home of 
some of the largest big pharma companies in the world.  Oxford and the Thames 
Valley do not have a pharma cluster with headquarter and R&D centers nearby.  This 
performance of Oxfordshire’s commercialization activity reflects national problems. 
In 2007, the UK was ranked as the fifth or sixth nation in the worldwide 
pharmaceutical market.  By 2013 it had fallen to 10th position.  Moreover, the share 
of the market attributable to products launched in the previous five years is lower than 
most comparable countries
16
 (interestingly Switzerland does not appear in the top 
ten).  Therefore, Oxfordshire’s research base necessarily has to collaborate with 
institutions outside of the region, especially the United States, by keeping historic ties 
that have been built up over the 20
th
 century in terms of mutual foreign direct 
investment (Dicken, 2015).  
 
3.4 Comparison with US/Boston/Massachusetts  
By way of contrast, we consider the scale and scope of activities in Boston which is 
the world’s leading biotech cluster, one which is tightly clustered (Breznitz and 
Anderson 2006), and has a mix of types of firms.  It is also one that has strong 
anchors (universities and big firms), attracts major amounts of money from public and 
                                                          
16
 http://www.abpi.org.uk/industry-info/knowledge-hub/global-industry/Pages/industry-market-.aspx 
(accessed February 26 2015). 
private sector organisations, has a very highly skilled labour force, and has developed 
a very strong infrastructural support system. 
  
The biotech cluster grew rapidly in the 1990s.  By 2002 there were 275 biotech firms 
employing over 26,000.  The dominant type of biotechnology activity is medical 
sciences, particularly human therapeutics (Breznitz and Anderson 2006).  By 2011, 
there were are more than 550 biotech and pharma companies located in Massachusetts 
(MassBio, 2011); 284 of these companies are drug development companies (Evaluate 
Pharma, 2014).  As of July 2014, there were 1,384 drugs in development by then in 
Massachusetts, from research project to pending approval stage.  These figures do not 
include the substantial number of drugs being developed in Massachusetts by 
companies with headquarters outside of the state.
17
  In 2013 there were 57,642 
biopharma employees in Massachusetts (2013) and the companies employing those 
workers are responsible for over $7.2 million of in-state payroll.  The Massachusetts 
biopharma industry grew by 41% between 2004 and 2013.  
 
The Boston area has a number of key anchor institutions.  For example, the 
Massachusetts General Hospital is the oldest in the US.  In conjunction with Harvard 
University it operates a major research facility and medical school.  In the area are 
also a number of hospitals including some of the nation's leaders in cancer (Dana 
Farber), arthritis (Brigham and Women's), cardiology (Lahey Clinic) and pediatrics 
(Children's Hospital).  Boston University and Tufts also have medical schools in the 
Metropolitan area and there is a substantial industry in medical equipment in Eastern 
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Massachusetts (Breznitz and Anderson 2006).  Massachusetts has 122 colleges and 
universities - over 40 of which offer advanced degrees in the life sciences, the top five 
National Institutes of Health-funded hospitals in the nation, and the highest educated 
workforce in the US. 
 
Funding for the sector in the state and Boston area from the national public sector is 
massive and underpins scientific and translational research.  Massachusetts received 
$2.3 billion in National Institutes of Health funding for basic research in Fiscal Year 
2013.  Massachusetts researchers receive over 11% of all NIH research funds.  On a 
per capita basis, Massachusetts receives over twice as much NIH funding (FY 2012) 
as the next closest state.  Massachusetts biotechnology companies received $984 
million in Venture Capital financings in 2013.  Massachusetts biotech companies 
received 21% of all US venture capital for biotech in 2013.  It ranks 1st in the nation 
in percentage of residents with a bachelors degree or higher.  Its elementary and 
secondary students outperform the rest of the nation in national assessments.  
 
The mix of firms is important (Malerba 2002).  There are a growing number of 
manufacturing assets in Massachusetts because of a workforce highly skilled in 
biologics process development.  In addition to a number of contract manufacturers, 
Massachusetts is also home to commercial manufacturing for Genzyme, Biogen-Idec, 
AbbVie, Shire, and Pfizer.  This makes it different to other bio-pharma clusters in 
North America (Spencer 2013) because it includes material inputs and outputs.  
Hence, as more of the innovation value chain is located in state, the potential for a 
greater range of spillovers is increased (Agarwal et al. 2007). 
 
Breznitz and Anderson (2006) in a survey of why biotech firms cluster in the 
Cambridge Massachusetts area found that the pool of skilled labor was the most 
important factor, followed by access to university labs (many of the founders came 
from university labs).  The former is linked to the universities which supply qualified 
people.  Access to hospitals was much lower.  However, as in other surveys e.g. 
Mckelvey et al. (2003) found that in Sweden, firms did not rate access to other firms 
as important, nor the availability of venture capital.  A study of the sector in 
Oxfordshire (Lawton Smith and Bagchi-Sen 2012) found that while the industry 
respondents did not rank the presence of universities as their top locational factor, 
they emphasized the presence of talent in science and technology as critically 
important to their operation.  Local talent, appears therefore to be the primary 
locational attribute in this sector, enabling firms to get the job done (see also 
McKelvey 2004, Gertler and Levitte 2005).  Thus what appears to be important from 
the literature – the mix of firms, universities labor markets need the addition of but 
not yet present – are systems of coordination. 
 
 
Table 4 about here 
 
There are two technology platforms where Oxford and Zurich show relative strengths 
i.e. research based on synchrotrons and microscopy.  All three appear to be 
developing newer technology platforms to a similar extent – those of genomics, 
proteomics and imaging.  Interestingly the disease platforms show similar patterns of 
past and present research/investment cancer greater than cardiovascular disease which 
is greater than immunology and infectious diseases which in turn is greater than 
neurodegenerative diseases.  There is likely to be vastly increased research/investment 
into neurodegenerative diseases (e.g. dementia) with global population ageing.   
 
The h-index is a convenient way of combining publications and citations.  However 
there is a temporal influence such that older publications have been exposed longer 
for potential citations.  As these findings are based on h-indices, it is not surprising 
that Boston shows higher results generally, but particularly where it reflects research 
investment in cardiovascular disease and cancer together with their associated clinical 
trials and life science related structural research.  Oxford follows this pattern to a 
lesser extent compared with Boston, but to a greater extent than Zurich.  The 
exceptions to Boston’s dominance are microscopy and research using a synchrotron 
where both European regions have greater access to these or one is available locally.  
Oxford and Zurich are similar for the most part on other measures. However, Zurich 
leads both Oxford and Boston in medicinal chemistry, which is typically low as this is 
likely dominated by pharmaceutical companies, of which there are many in 




This study considers two exemplar regions Oxfordshire and Zurich to illustrate 
similarities and differences in inputs, infrastructure and outputs.  These depict 
innovation capacity in the broader life sciences which includes academics, industry, 
as well healthcare and/or clinical facilities.  In addition, the study contrasts these two 
regions with one of the leaders in this broad sector, Boston/Cambridge Massachusetts.  
It has taken three geographical scales - national, regional and organizational - to 
reflect on what makes them unique and therefore how they differ in their development 
to others with some similarities in research and industry characteristics. 
 
The results show each location’s position as leaders in their national as well as 
international systems of innovation.  Oxford excels in terms of inputs (e.g., science 
base). In particular, at the organizational level, Oxford has academic excellence as 
indicated by the very high level of publications in leading journals.  This in part is 
related to the necessity of Oxford University’s academics maintaining its leading 
world rankings thus enabling it to attract the best staff and students as well as research 
income.   
 
However, at the regional level, Oxford’s performance as a diffuser of innovation 
through the formation and growth of spin-off firms (Agrawal et al. 2007) appears to 
be focused on generating startups/small companies that are later bought out by bigger 
players thus removing the potential for the growth of anchor firms (Feldman 2003, 
Spencer 2013).  Oxford University does not appear to be an anchor institution other 
than in research (see Autant-Bernard et al.  2006), and therefore is not as a leader of 
innovation, and its contribution to regional innovation capacity is limited except in 
specific respects.  Here Oxford is similar to Boston as it follows the same pattern of 
focus on cardiovascular disease, cancer and clinical trials but to a lesser extent.  
Moreover, there is a smaller pool of graduates in the healthcare disciplines than in 
Zurich which also limits feed into translational research. 
 
However, parts of an innovation support system are in place – such as the space on 
science and business parks, while the lack of a bioincubator is being addressed. 
However, some of the more structural problems include an absence of R&D intensive 
big pharma anchor firms (Agrawal and Cockburn 2003) and the kind of public sector 
support which is needed for a RIS (Cooke 1992 & 1998, Asheim and Coenen 2005) 
which is present in Massachusetts.  
 
Zurich and Switzerland which has a generally healthier population, appears to have 
better funding than Oxford generally and possibly its academics have less pressure to 
publish in top journals.  Zurich appears to have greater innovation capacity being 
better at growing companies than Oxfordshire and also benefits from of the presence 
of big pharma (see Feldman 2003, Spencer 2013).  With respect to diffusion of 
innovation (Agrawal et al. 2007), Zurich is similar to Boston as it appears to invest 
comparatively more in technologies.  
 
There is evidence here, therefore, to support Jong (2008) and Jong and Slavova 
(2014) that organizational behavior and academics’ links with industry vary by 
academic experience and by place.  In Oxfordshire and Zurich, this is also related to 
varying levels of research funding and supply of graduates.  This is reflected in 
Oxfordshire’s position in the national sectoral system of innovation (Malerba 2002, 
2005) as being at the exploration stage compared to Zurich’s greater capacity for 
innovation at the exploitation stage.  That said, both regions have the base to become 
bigger and better in discovery, therapeutics, diagnostics, clinical research etc.  
 
However, this does not make generalizations with respect to policy easy.  Each region 
follows its own pathway in which individuals make their own choices about 
collaboration in the light of funding opportunities.  Therefore in this complex 
industry,  specific policies necessarily relate to what each cluster has done so far and 
what it could do in the future based on current assets. 
 
Moreover, it is difficult to quantify micro-geographies, that is, the location of 
departments within a campus, the culture of collaboration in universities, the tradition 
and practice of reaching out to scientists in institutes and industry for furthering 
translational research, and finally, the tolerance of funding agencies to lag times and 
failures.  While a field trip to Stanford, Berkeley, and MIT would show how various 
types of proximity can work, in other places, this is not as apparent.  This lack of 
transparency may be the “unquantifiable” that cannot be captured and operationalized 
by one agent (e.g., policymaker) or by one firm. 
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Tables Innovation pathways 
 
Table 1: Innovation Indicators for Inputs in Oxford and Zurich 
 Oxford Zurich 
Profs H-factor >30 238 231 
Publications 2264 1190 
Research spending/funding (mio Euro) 633 1042 
International graduated MSc students 148 348 
International PhD students 345 2762 
National graduated MSc students 193 1212 
National PhD students 805 2167 
Junior ERC grants 16 17 
Senior ERC grants 19 33 
Research m2 98,249 315,000 
Research hospital beds 4727 2258 
Clinical trials 8 2 
Source: HealthTIES 
 
 Table 2: Innovation Indicators for the Innovation System in Oxford and Zurich 
 Oxford Zurich 
Spin-offs 36 33 
Granted US patents 50 40 
W.A.I.T. indicator (Oxford *estimated in chart) n/a  140 
Joint research projects 59 41 
TTO FTEs 89 37.6 
Governmental innovation support (Government procurement 
of advanced technology products) WEF GCR  3.8 4.4 
Regional attractiveness, WEF GCR index 5.25 5.63 
Science parks m2 312,528 88,700 
Science parks FTEs 49 17.75 
Source: HealthTIES 
Table 3: Innovation Indicators for Outputs in Oxford and Zurich 
 Oxford Zurich 
FTEs working in HT disciplines 13,563 34,440 
Companies <20 FTEs 154 1,449 
Companies >20 FTEs 46 262 
Big trade sales 4 2 
Products on market 122 282 
Products phase I-III + NDA 66 43 
Products in discovery phase 49 37 
Medicines available in countries n/a 37 
Total investments (Mio Euro) 420.75 130.30 
# investments 20 16 
Average Series A investments (Mio Euro) 9.10 3.97 
Source: HealthTIES 
 Table 4: Scientific indicators for disease and technology platforms 
 Oxford Zurich Boston 
Cardiovascular 102 58 229 
Cancer 167 111 430 
Neurodegeneration 52 38 88 
Immunology and Infection 70 55 117 
Proteomics 31 58 73 
Genomics 45 35 77 
Structure 130 127 280 
Microscopy 114 126 111 
Synchrotron 52 38 29 
Imaging 58 52 112 
Medicinal Chemistry 9 18 12 
Clinical Trials 124 73 380 
Drug Delivery 34 43 84 
Drug Development 65 65 125 
Source: HealthTIES 
 
 
 
